Disseminated Lung Metastases in Thyroid Cancer

Research output: Contribution to journalArticle

Abstract

A 23-year-old female suffered from a locally invasive well-differentiated thyroid papillary carcinoma with cervical lymph nodes metastases and disseminated lung metastases 16 years ago (in 1989). After undergoing a surgical operation, she had received subsequent accumulated therapeutic dose of 13 GBq (350 mCi) of 131I in the following two years. Thereafter, she delivered two healthy babies in 1993 and in1996, respectively. Ten years later (in 1999), persistent disseminated lung metastases were identified with a 7.4 GBq 131I post-therapy scan. Meanwhile, FDG-PET study was negative. In 2005, she received FDG-PET study, 131I therapy, and post-therapy 131I scan using the injection of recombinant human TSH instead of thyroxin withdrawal. The result showed nearly resolution of the metastatic lesions. The establishment of diagnostic/treatment guideline, the introduction of metabolic imaging modality, and the invention and production of recombinant human TSH in the past decade, this patient is able to receive accurate diagnosis, therapy and follow-up.
Original languageEnglish
Pages (from-to)247-252
Number of pages6
Journal核子醫學雜誌
Volume18
Issue number4
DOIs
Publication statusPublished - 2005

Fingerprint

Thyroid Neoplasms
Neoplasm Metastasis
Lung
Thyrotropin Alfa
Therapeutics
Thyroxine
Lymph Nodes
Guidelines
Injections

Keywords

  • 甲狀腺癌
  • 散播性肺轉移
  • FDG-PET
  • thyroid cancer
  • disseminated lung metastases

Cite this

Disseminated Lung Metastases in Thyroid Cancer. / Hsu, Chung-Huei.

In: 核子醫學雜誌, Vol. 18, No. 4, 2005, p. 247-252.

Research output: Contribution to journalArticle

@article{028bd72ad6704f858b5bc27d43515279,
title = "Disseminated Lung Metastases in Thyroid Cancer",
abstract = "A 23-year-old female suffered from a locally invasive well-differentiated thyroid papillary carcinoma with cervical lymph nodes metastases and disseminated lung metastases 16 years ago (in 1989). After undergoing a surgical operation, she had received subsequent accumulated therapeutic dose of 13 GBq (350 mCi) of 131I in the following two years. Thereafter, she delivered two healthy babies in 1993 and in1996, respectively. Ten years later (in 1999), persistent disseminated lung metastases were identified with a 7.4 GBq 131I post-therapy scan. Meanwhile, FDG-PET study was negative. In 2005, she received FDG-PET study, 131I therapy, and post-therapy 131I scan using the injection of recombinant human TSH instead of thyroxin withdrawal. The result showed nearly resolution of the metastatic lesions. The establishment of diagnostic/treatment guideline, the introduction of metabolic imaging modality, and the invention and production of recombinant human TSH in the past decade, this patient is able to receive accurate diagnosis, therapy and follow-up.",
keywords = "甲狀腺癌, 散播性肺轉移, FDG-PET, thyroid cancer, disseminated lung metastases",
author = "Chung-Huei Hsu",
year = "2005",
doi = "10.6332/ANMS.1804.009",
language = "English",
volume = "18",
pages = "247--252",
journal = "核子醫學雜誌",
issn = "1022-923X",
publisher = "中華民國核子醫學學會",
number = "4",

}

TY - JOUR

T1 - Disseminated Lung Metastases in Thyroid Cancer

AU - Hsu, Chung-Huei

PY - 2005

Y1 - 2005

N2 - A 23-year-old female suffered from a locally invasive well-differentiated thyroid papillary carcinoma with cervical lymph nodes metastases and disseminated lung metastases 16 years ago (in 1989). After undergoing a surgical operation, she had received subsequent accumulated therapeutic dose of 13 GBq (350 mCi) of 131I in the following two years. Thereafter, she delivered two healthy babies in 1993 and in1996, respectively. Ten years later (in 1999), persistent disseminated lung metastases were identified with a 7.4 GBq 131I post-therapy scan. Meanwhile, FDG-PET study was negative. In 2005, she received FDG-PET study, 131I therapy, and post-therapy 131I scan using the injection of recombinant human TSH instead of thyroxin withdrawal. The result showed nearly resolution of the metastatic lesions. The establishment of diagnostic/treatment guideline, the introduction of metabolic imaging modality, and the invention and production of recombinant human TSH in the past decade, this patient is able to receive accurate diagnosis, therapy and follow-up.

AB - A 23-year-old female suffered from a locally invasive well-differentiated thyroid papillary carcinoma with cervical lymph nodes metastases and disseminated lung metastases 16 years ago (in 1989). After undergoing a surgical operation, she had received subsequent accumulated therapeutic dose of 13 GBq (350 mCi) of 131I in the following two years. Thereafter, she delivered two healthy babies in 1993 and in1996, respectively. Ten years later (in 1999), persistent disseminated lung metastases were identified with a 7.4 GBq 131I post-therapy scan. Meanwhile, FDG-PET study was negative. In 2005, she received FDG-PET study, 131I therapy, and post-therapy 131I scan using the injection of recombinant human TSH instead of thyroxin withdrawal. The result showed nearly resolution of the metastatic lesions. The establishment of diagnostic/treatment guideline, the introduction of metabolic imaging modality, and the invention and production of recombinant human TSH in the past decade, this patient is able to receive accurate diagnosis, therapy and follow-up.

KW - 甲狀腺癌

KW - 散播性肺轉移

KW - FDG-PET

KW - thyroid cancer

KW - disseminated lung metastases

U2 - 10.6332/ANMS.1804.009

DO - 10.6332/ANMS.1804.009

M3 - Article

VL - 18

SP - 247

EP - 252

JO - 核子醫學雜誌

JF - 核子醫學雜誌

SN - 1022-923X

IS - 4

ER -